Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F1JD
|
|||
| Drug Name |
Apabetalone
|
|||
| Synonyms |
RVX 000222; 1044870-39-4; 2-(4-(2-Hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one; RVX-000222; 2-[4-(2-Hydroxyethoxy)-3,5-Dimethylphenyl]-5,7-Dimethoxyquinazolin-4(3h)-One; UNII-8R4A7GDZ1D; RVX 000222; 8R4A7GDZ1D; QC-216; AK110565; Apabetalone [INN]; RVX000222; Apabetalone [USAN:INN]; 1K0; 4mr4; 4mr6; 4j1p; 4j3i; Apabetalone (USAN/INN); D0N7WW; SCHEMBL145019; GTPL7034; SCHEMBL17002023; AOB2133; DTXSID90146502; MolPort-027-835-445; NETXMUIMUZJUTB-UHFFFAOYSA-N; HMS3653C10; EX-A1110; BCP07787; ZINC4319
Click to Show/Hide
|
|||
| Indication | Cardiac events [ICD-11: MC82] | Phase 3 | [1] | |
| Cardiovascular disease [ICD-11: BA00-BE2Z] | Phase 3 | [2] | ||
| Company |
Resverlogix San Francisco, CA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H22N2O5
|
|||
| Canonical SMILES |
CC1=CC(=CC(=C1OCCO)C)C2=NC3=C(C(=CC(=C3)OC)OC)C(=O)N2
|
|||
| InChI |
1S/C20H22N2O5/c1-11-7-13(8-12(2)18(11)27-6-5-23)19-21-15-9-14(25-3)10-16(26-4)17(15)20(24)22-19/h7-10,23H,5-6H2,1-4H3,(H,21,22,24)
|
|||
| InChIKey |
NETXMUIMUZJUTB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1044870-39-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.